Avantel Merger Plan Streamlines Imeds Operations in 2026

Board approves subsidiary merger

Avantel Limited's board approved the merger of Imeds Global Private Limited, its wholly owned subsidiary, into the parent company on September 18, 2026. The proposal was considered under Sections 230 to 232 of the Companies Act, 2013. Imeds Global will be the transferor company and Avantel will be the transferee company under the proposed scheme. The company said the transaction is intended to rationalise the group structure, consolidate operations and improve operational efficiency. The board also approved changes to Avantel's Memorandum of Association, or MoA. Those changes would broaden the company's permitted business objects across several technology and manufacturing fields. The MoA proposal requires shareholder approval through a postal ballot. The merger remains subject to approvals from the National Company Law Tribunal and other statutory authorities.

No cash payment or new share issue

The transaction does not involve cash consideration, a share swap or an issue of new Avantel shares. This structure follows from Imeds Global being 100% owned by Avantel. The Avantel shares held in Imeds Global will be cancelled once the scheme becomes effective. As no new shares are proposed to be allotted, Avantel's shareholding pattern will not change because of the merger. The filing also states that the transaction is exempt from related-party transaction requirements under Regulation 23(5)(b) of the SEBI Listing Obligations and Disclosure Requirements Regulations. The structure makes the proposal an internal consolidation rather than an acquisition involving external shareholders. The final implementation, however, depends on the required corporate and regulatory process.

Imeds Global operates in medical electronics

Imeds Global's stated business includes the design, development and manufacturing of medical electronic devices and healthcare solutions. Its focus areas include respiratory care, patient monitoring, surgical instruments, endoscopy and homecare solutions. The merger would bring these activities directly within Avantel rather than retaining them in a separate subsidiary. Avantel's board also proposed adding medical devices, healthcare equipment and healthcare IT services to the main objects clause of its MoA. This proposed change is directly relevant to the subsidiary's stated business. Shareholder approval is needed before the MoA alteration can take effect. The proposed merger and MoA amendment were approved at the same board meeting in Hyderabad. The meeting started at 10:30 am and concluded at 3:10 pm.

FY26 financial data reported in filings

The disclosures provide FY26 financial data for both companies. Imeds Global reported revenue of ₹16.03 crore and net worth of ₹218.28 crore. Avantel reported revenue of ₹2,213.52 crore and net worth of ₹3,565.05 crore in the filing summary. A separate disclosure described Imeds Global's standalone revenue as ₹1.60 crore and net worth as ₹21.83 crore, while stating that it represented less than 1% of Avantel's FY26 standalone revenue of ₹221.35 crore. The supplied disclosures therefore contain differently presented financial figures across filing summaries. The merger terms do not depend on an exchange ratio because Imeds Global is wholly owned. No valuation-based share allotment has been proposed in the stated transaction structure.

Key merger details

MoA changes cover additional business areas

The board approved the insertion of additional main objects into Avantel's MoA, subject to the postal ballot and other required approvals. The proposed objects cover medical devices, healthcare technology, telemedicine and life sciences research. They also include satellite systems, space technology, ground station services and remote sensing. Other listed areas are energy systems involving nuclear, solar, wind, hydrogen and battery storage. The expanded objects further cover mechanical, electrical and electronic manufacturing services. Microelectronics, semiconductor packaging and testing facilities are also included. Artificial intelligence, machine learning, cybersecurity and data centres form part of the proposed additions. These approvals would expand the company's formal operating scope, but the filing does not state any immediate project, investment or revenue target for these areas.

Postal ballot schedule

Avantel approved the notice for the postal ballot seeking shareholder consent for the MoA alteration. Remote e-voting began at 9:00 am on September 23, 2026. The voting window is scheduled to close at 5:00 pm on October 22, 2026. Voting results are scheduled to be declared on October 23, 2026. The merger itself is subject to the separate approvals required under the Companies Act process. The board had first informed the BSE on September 12 that it would consider the merger at its September 18 meeting. The subsequent board approval converted that proposal into a formal scheme subject to the stated conditions. Investors will need to track the postal ballot result and the progress of statutory approvals.

Why the transaction matters

The merger is designed to remove the separate corporate layer between Avantel and Imeds Global. With the subsidiary wholly owned, Avantel has stated that consolidating operations can reduce administrative duplication and support operational efficiency. The absence of cash consideration, share issuance or ownership dilution limits the immediate capital-structure impact described in the filing. The proposed MoA changes are broader than the merger itself and cover healthcare, space and satellite technology, energy systems, advanced manufacturing, semiconductors and AI-related activities. These changes provide the company with authority to pursue activities in those fields if the required approvals are obtained. They do not, on their own, confirm the start of a new business line or a specific financial outcome. The reported next milestones are the October 23 postal ballot result and the statutory approval process for the merger.

Outlook based on disclosed steps

Avantel has completed board-level approval for the merger of Imeds Global into the parent entity. The company has also initiated the shareholder voting process for the MoA alteration. If the scheme receives the required statutory approvals, Imeds Global will be consolidated into Avantel and the parent company's holding in the subsidiary will be extinguished. No cash payment or fresh share allotment is planned under the approved scheme. The company has not disclosed a date when the merger will become effective. The immediate disclosed timetable is the conclusion of e-voting on October 22 and the announcement of results on October 23, 2026.